HK1076474A1 - Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours - Google Patents
Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumoursInfo
- Publication number
- HK1076474A1 HK1076474A1 HK05108339.8A HK05108339A HK1076474A1 HK 1076474 A1 HK1076474 A1 HK 1076474A1 HK 05108339 A HK05108339 A HK 05108339A HK 1076474 A1 HK1076474 A1 HK 1076474A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tumours
- fibronectin
- conjugates
- domain
- detection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02000315 | 2002-01-03 | ||
US35870202P | 2002-02-25 | 2002-02-25 | |
PCT/EP2003/000009 WO2003055917A2 (fr) | 2002-01-03 | 2003-01-02 | Nouvelles methodes de diagnostic et de traitement de tumeurs |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1076474A1 true HK1076474A1 (en) | 2006-01-20 |
Family
ID=26077560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05108339.8A HK1076474A1 (en) | 2002-01-03 | 2005-09-22 | Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours |
Country Status (15)
Country | Link |
---|---|
US (1) | US20040001790A1 (fr) |
EP (2) | EP1461360B1 (fr) |
JP (2) | JP2005523887A (fr) |
CN (1) | CN1612895B (fr) |
AU (1) | AU2003210149B2 (fr) |
BR (1) | BR0306715A (fr) |
CA (1) | CA2468081A1 (fr) |
CY (1) | CY1110923T1 (fr) |
HK (1) | HK1076474A1 (fr) |
IL (2) | IL162201A0 (fr) |
MX (1) | MXPA04006517A (fr) |
NO (1) | NO20043246L (fr) |
PL (1) | PL369371A1 (fr) |
RU (1) | RU2352582C2 (fr) |
WO (1) | WO2003055917A2 (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9610967D0 (en) * | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
US20030176663A1 (en) * | 1998-05-11 | 2003-09-18 | Eidgenossische Technische Hochscule | Specific binding molecules for scintigraphy |
US20030045681A1 (en) * | 1998-05-11 | 2003-03-06 | Anthony J. Zelano | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
JP2003524018A (ja) | 2000-02-24 | 2003-08-12 | アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ | フィブロネクチンのed‐bドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用 |
PL364358A1 (en) * | 2000-09-07 | 2004-12-13 | Schering Ag | Receptor in the edb fibronectin domain (ii) |
WO2003076469A2 (fr) * | 2002-03-11 | 2003-09-18 | Philogen S.P.A. | Ciblage selectif d'un systeme vasculaire tumoral au moyen de molecules d'anticorps |
EP1514561A1 (fr) * | 2003-09-10 | 2005-03-16 | Philogen S.p.A. | Ciblage de la vasculature tumorale avec l'utilisation de l'anticorps radio-marqué L19 contre le fibronectin ED-B |
DE10348319A1 (de) * | 2003-10-17 | 2005-05-19 | Schering Ag | Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques |
US20060039863A1 (en) * | 2004-07-22 | 2006-02-23 | Michael Schirner | Use of cyanine dyes for the diagnosis of disease associated with angiogenesis |
EP1619501B1 (fr) * | 2004-07-22 | 2007-09-26 | Bayer Schering Pharma Aktiengesellschaft | Utilisation des colorants cyanines dans le diagnostic des maladies associées à l'angiogénèse |
US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
ES2291071B1 (es) * | 2005-06-13 | 2009-03-16 | Proyecto De Biomedicina Cima, S.L. | Agentes y metodos basados en el uso del dominio eda de la fibronectina. |
CA2650953A1 (fr) * | 2006-05-03 | 2007-11-15 | Bayer Schering Pharma Aktiengesellschaft | Combinaison d'un anticorps l19-sip anti domaine ed-b de la fibronectine et d'un anticorps anti-egfr |
EP2653478B1 (fr) * | 2007-04-02 | 2016-10-05 | Philogen S.p.A. | Nouvel antigène associé à la néovasculature de métastases tumorales |
EP2036576A1 (fr) * | 2007-09-17 | 2009-03-18 | Bayer Schering Pharma Aktiengesellschaft | Fibronectine ED-B en tant que marqueur de stratification pour médicaments anti-tumeurs |
US8253725B2 (en) * | 2007-12-28 | 2012-08-28 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Method and system for generating surface models of geometric structures |
EP2116555A1 (fr) | 2008-05-08 | 2009-11-11 | Bayer Schering Pharma Aktiengesellschaft | Utilisation d'une molécule radiomarquée se liant spécifiquement à la fibronectine ED-B dans un procédé de traitement du lymphome Hodgkin |
CN102596258B (zh) | 2009-07-22 | 2015-01-28 | 锕医药股份有限公司 | 用于制备放射性免疫缀合物的方法 |
EP2518086A1 (fr) * | 2009-12-25 | 2012-10-31 | Riken | Composé radiomarqué dirigeable in vivo vers un tissu cible et son utilisation |
WO2011110490A1 (fr) | 2010-03-09 | 2011-09-15 | Bayer Pharma Aktiengesellschaft | Procédé pour la production de fragments d'anticorps scfv marqués radioactivement, kits et compositions |
CN104215668A (zh) * | 2014-08-25 | 2014-12-17 | 浙江大学 | 基于theed纤维阵列的二氧化碳传感器及其制备方法 |
EP3378947B1 (fr) * | 2015-11-16 | 2024-01-24 | Hefei Lifeon Pharmaceutical Co. Ltd. | Utilisation de protéine ed-b dans le diagnostic d'une hyperplasie tissulaire |
SG11201903400WA (en) * | 2016-10-17 | 2019-05-30 | Pfizer | Anti-edb antibodies and antibody-drug conjugates |
US11872288B2 (en) | 2020-05-22 | 2024-01-16 | Philogen S.P.A. | TNF-alpha immunoconjugate therapy for the treatment of brain tumors |
KR20240034234A (ko) | 2021-07-14 | 2024-03-13 | 2세븐티 바이오, 인코포레이티드 | 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체 |
WO2023196997A2 (fr) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Récepteur multipartite et complexes de signalisation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2065299C (fr) * | 1989-08-09 | 2001-07-24 | Buck A. Rhodes | Radio-etiquetage direct des anticorps et d'autres proteines a l'aide de technetium ou de rhenium |
EP0625200B1 (fr) * | 1992-02-06 | 2005-05-11 | Chiron Corporation | Proteine de liaison biosynthetique pour marqueur de cancer |
GB9324807D0 (en) * | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
TWI259837B (en) | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
US6171578B1 (en) * | 1999-04-14 | 2001-01-09 | Diatide, Inc. | Benzodiazepine derivatives for imaging thrombi |
JP4926320B2 (ja) * | 1999-04-28 | 2012-05-09 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Vegfの選択的阻害による癌処置のための組成物および方法 |
JP2003524018A (ja) | 2000-02-24 | 2003-08-12 | アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ | フィブロネクチンのed‐bドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用 |
-
2003
- 2003-01-02 AU AU2003210149A patent/AU2003210149B2/en not_active Revoked
- 2003-01-02 IL IL16220103A patent/IL162201A0/xx unknown
- 2003-01-02 WO PCT/EP2003/000009 patent/WO2003055917A2/fr active Application Filing
- 2003-01-02 RU RU2004123785/13A patent/RU2352582C2/ru not_active IP Right Cessation
- 2003-01-02 JP JP2003556447A patent/JP2005523887A/ja not_active Withdrawn
- 2003-01-02 BR BR0306715-7A patent/BR0306715A/pt not_active Application Discontinuation
- 2003-01-02 MX MXPA04006517A patent/MXPA04006517A/es active IP Right Grant
- 2003-01-02 CA CA002468081A patent/CA2468081A1/fr not_active Withdrawn
- 2003-01-02 PL PL03369371A patent/PL369371A1/xx unknown
- 2003-01-02 CN CN038019434A patent/CN1612895B/zh not_active Withdrawn - After Issue
- 2003-01-02 EP EP03726977A patent/EP1461360B1/fr not_active Expired - Lifetime
- 2003-01-02 EP EP10162295A patent/EP2239274A1/fr not_active Withdrawn
- 2003-01-03 US US10/336,041 patent/US20040001790A1/en not_active Abandoned
-
2004
- 2004-05-27 IL IL162201A patent/IL162201A/en not_active IP Right Cessation
- 2004-08-02 NO NO20043246A patent/NO20043246L/no unknown
-
2005
- 2005-09-22 HK HK05108339.8A patent/HK1076474A1/xx not_active IP Right Cessation
-
2009
- 2009-05-29 JP JP2009129965A patent/JP4663020B2/ja not_active Expired - Lifetime
-
2010
- 2010-11-17 CY CY20101101038T patent/CY1110923T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2003210149B2 (en) | 2008-10-09 |
CY1110923T1 (el) | 2015-06-10 |
EP1461360B1 (fr) | 2010-08-18 |
RU2004123785A (ru) | 2005-08-10 |
JP4663020B2 (ja) | 2011-03-30 |
CA2468081A1 (fr) | 2003-07-10 |
JP2005523887A (ja) | 2005-08-11 |
EP2239274A1 (fr) | 2010-10-13 |
WO2003055917A2 (fr) | 2003-07-10 |
WO2003055917A3 (fr) | 2003-12-24 |
US20040001790A1 (en) | 2004-01-01 |
AU2003210149A1 (en) | 2003-07-15 |
IL162201A (en) | 2011-04-28 |
BR0306715A (pt) | 2004-12-28 |
JP2009209149A (ja) | 2009-09-17 |
CN1612895B (zh) | 2010-05-12 |
IL162201A0 (en) | 2005-11-20 |
CN1612895A (zh) | 2005-05-04 |
PL369371A1 (en) | 2005-04-18 |
NO20043246L (no) | 2004-08-02 |
EP1461360A2 (fr) | 2004-09-29 |
MXPA04006517A (es) | 2005-03-31 |
RU2352582C2 (ru) | 2009-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1076474A1 (en) | Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours | |
AU4243201A (en) | Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis | |
HUS1700013I1 (hu) | Humán tumor nekrózis faktor-alfa specifikus antitest molekulák és alkalmazásuk | |
IL183458A0 (en) | Anti-il-1r1 single domain antibodies and therapeutic uses | |
HK1089155A1 (en) | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | |
IL173080A0 (en) | Assay for human anti cd20 antibodies and uses therefor | |
EP1799262A4 (fr) | Anticorps anti-cd70 et son utilisation pour le traitement et la prevention du cancer et des troubles immunitaires | |
EP1814909A4 (fr) | Utilisation de aimp2dx2 pour diagnostiquer et traiter un cancer | |
SG104356A1 (en) | Absorbent body and absorbent article having the absorbent body | |
EP1487492A4 (fr) | Prevention ou traitement de cancer au moyen d'antagonistes de l'integrine alphavbeta3 combines a d'autres agents | |
EP1578380A4 (fr) | Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate | |
EP1355563A4 (fr) | Procedes de prevention et de traitement du cancer au moyen d'anticorps anti-c3b(i) | |
IL180278A0 (en) | Fused pyrimidones useful in the treatment and the prevention of cancer | |
EP1909827A4 (fr) | Modulation de l'immunite et de l'activite de ceacam1 | |
AU303012S (en) | Sanitary napkin | |
AU2003227148A8 (en) | Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer | |
ZA200503618B (en) | Single domain antibodies directed against Tumour Necrosis Factor-alpha and uses therefor | |
AU2003215381A1 (en) | EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER | |
GB2400176B (en) | Ultrasound probe and application thereof | |
PL371202A1 (en) | Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine | |
AU2002327643A1 (en) | Detection and treatment of cancers of the liver | |
EP1684795A4 (fr) | Procedes et agents pour le traitement du cancer | |
PT1680405E (pt) | Derivados de bengamida e sua utilização para o tratamento de doenças cancerosas | |
AU2003211292A1 (en) | Monoclonal antibody against human hepatoma and use thereof | |
ZA200703306B (en) | Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent surrendered | ||
PS | Patent surrendered |